ADALIMUMAB

ADALIMUMAB (12390D)

adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices
12390D
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $494.12 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Hadlima
Humira
Hyrimoz
Yuflyma